Starling Oncology
STLN
39 hedge funds and large institutions have $15.3M invested in Starling Oncology in 2023 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 17 increasing their positions, 9 reducing their positions, and 8 closing their positions.
89% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 9
3.06% less ownership
Funds ownership: 32.52% → 29.46% (-3.1%)
5% less funds holding
Funds holding: 41 → 39 (-2)
25% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 8
61% less capital invested
Capital invested by funds: $39.2M → $15.3M (-$23.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TM
Triatomic Management
Palo Alto,
California
|
+$373K |
| 2 |
Renaissance Technologies
New York
|
+$169K |
| 3 |
Jane Street
New York
|
+$60.1K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$56.2K |
| 5 |
Allspring Global Investments
Charlotte,
North Carolina
|
+$32K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$1.61M |
| 2 |
BlackRock
New York
|
-$864K |
| 3 |
JFG
Jefferies Financial Group
New York
|
-$318K |
| 4 |
AGM
Alpine Global Management
New York
|
-$76K |
| 5 |
Corient Private Wealth
Miami,
Florida
|
-$21K |
STLN Hedge Fund Activity: Q1 2023 in Review
39 of the 6,284 institutional investors tracked by Wall St. Rank reported a position in Starling Oncology (STLN) for Q1 2023, worth a combined $15.3M — down 61% from $39.2M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of STLN and 6 opened new positions — a net loss of 2 holders — while 9 trimmed existing stakes and 17 added.
The largest buyer was Triatomic Management, adding an estimated $373K. The largest seller was Redmile Group, cutting an estimated $1.61M.
- 39 institutional investors held Starling Oncology (STLN) as of Q1 2023, down from 41 in Q4 2022.
- Funds reported $15.3M of Starling Oncology stock for Q1 2023, down 61% quarter-over-quarter.
- 6 funds opened new Starling Oncology positions in Q1 2023 and 8 closed out, a net change of -2 holders.
- The largest Starling Oncology buyer in Q1 2023 was Triatomic Management, an estimated $373K added.
- The largest Starling Oncology seller in Q1 2023 was Redmile Group, an estimated $1.61M sold.
Based on aggregated 13F filings for Q1 2023.